Search

Search Constraints

You searched for: Author/Creator Altan, Mehmet

Search Results

1. 277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy. (9th November 2020)

2. 277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy. (9th November 2020)

3. 283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs). (9th November 2020)

4. 376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors. (9th November 2020)

5. 658 Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases. (9th November 2020)

6. 658 Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases. (9th November 2020)

8. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. (2021)

9. Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. Issue 1 (17th December 2019)

10. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis. Issue 1 (2nd April 2019)